Motley Fool Weighs Amgen and Moderna as Top Biotech Picks for 2026
AI-generated from multiple sources. Verify before acting on this reporting.
SAN FRANCISCO — The Motley Fool published a comparative analysis on Wednesday evaluating Amgen Inc. and Moderna Inc. as potential investment opportunities leading into the final months of 2026. The financial advice publication sought to determine which of the two biotechnology giants offers superior growth prospects for investors navigating the current market landscape.
The report, released on September 10, 2026, contrasts the established revenue streams of Amgen against the vaccine-focused innovation pipeline of Moderna. Amgen, a veteran in the pharmaceutical sector, is highlighted for its diversified portfolio of treatments targeting chronic conditions such as osteoporosis, cancer, and cardiovascular disease. The analysis suggests that Amgen's mature business model provides a degree of stability and consistent dividend yield that appeals to conservative investors seeking lower volatility.
Conversely, Moderna is positioned as a high-growth candidate driven by its mRNA technology platform. While the company initially gained prominence for its COVID-19 vaccine, the report notes its strategic pivot toward developing treatments for influenza, respiratory syncytial virus (RSV), and various oncology applications. The publication argues that if Moderna successfully advances these new candidates through clinical trials and secures regulatory approvals, the stock could deliver significant capital appreciation compared to traditional pharma peers.
The comparison addresses the divergent risk profiles inherent in each company. Amgen faces challenges related to patent expirations on key drugs and increasing pressure from generic competition, which could compress profit margins over the next 18 months. In contrast, Moderna's valuation remains sensitive to clinical trial data readouts and the competitive dynamics of the global vaccine market. The analysis indicates that while Amgen offers a defensive posture, Moderna presents an aggressive growth thesis contingent on future product success.
Market conditions in late 2026 have intensified scrutiny on biotech valuations, with interest rates and regulatory environments playing critical roles in stock performance. The Motley Fool's assessment does not issue a definitive buy or sell order but rather outlines the fundamental arguments supporting each ticker. It emphasizes that the choice between the two depends heavily on an investor's time horizon and risk tolerance.
As of Wednesday's close, both stocks have shown mixed trading activity following the release of the analysis. The broader biotechnology sector continues to monitor upcoming FDA decisions and quarterly earnings reports that could further influence investor sentiment. Questions remain regarding how sustained healthcare policy changes in the United States will impact pricing power for both companies in the coming fiscal year. Investors are closely watching whether Moderna can replicate its pandemic-era success with new indications or if Amgen's steady cash flow will prove more resilient in a fluctuating economic climate.